Clinical Trials Study
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2014; 20(46): 17498-17506
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17498
Table 1 Clinical and histopathological features of the patients included in the study group
Case No.SexAgeDiagnosis (WHO 2010)Mitotic scoreKi67Tumor size (cm)TNM (UICC)
P01F45NET G1< 1< 1%3.5pT2, pN0(0/10), pM1, L0, V0, pN0
P02F77NET G223%14pT3, pN1, pMx, L1, V1, pN0
P03M45NET G1< 11%2.3pT2, pNx, pMx, L0, V0, pN0
P04M57NET G1110%3.8pT3, pN0, pM1, L1, V0, pN0, G1
P05M50NET G1< 10.4%1.1pT1, pNx, pMx, L0, V0, pN0, G1
P06M61NET G1< 12.6%5pT3, pN0 (0/5), pMx, L0, V0, pN0, G1
P07F77NET G32535%10pT3, pN0, pMx, L1, V0, pN0
P08M58NET G1< 1< 1%0.3pT1, pNx, pMx, L0, V0, pN0, G1
P09M33NET G224.7%2.8pT2, pN1 (2/26), pMx, L1, V0, pN0, G2
P10M50NET G2512.4%> 20pT4, pNx, pM1, L1, V1, pN1, G2
P11F16NET G2316.1%5pT3, pN1 (19/68), pM1, L1, V0, pN1, G2
P12F33NET G221.2%2pT1, pN0, pMx, L0, V0, pN0, G2
P13F38NET G227%5.5pT3, pN1 (2/15), pM1, L1, V0, pN1, G2
P14M58NET G2106.5%4.5pT3, pN1(8/23), pMx, L0, V1, pN1, G2
P15M72NET G1< 11.5%1.5pT1, pNx, pM1, L0, V0, pN0, G1
P16F60NET G1< 10.5%1.1pT1, pN0 (0/6), pMx, L0, V0, pN0, G1
P17F77NET G1< 10.8%1pT1, pNx, pMx, L0, V0, pN0 ,G1
P18F49NET G1< 11.4%2.7pT2, pN0 (0/5), pMx, L1, V0, pN0, G1
P19F52NET G2514.6%4pT3, pN0, pM1, L1, V1, pN1, G2
P20F46NET G116%9.5pT2, pN0(0/9), pMx,L1,V1,pN0, G1
P21M55NET G1< 12.9%3pT3, pN1 /1/15), pM1, V0, L1, pN0, G1
P22M31NET G112.2%0.9pT1, pN0 (0/5), pMx, L0, V0, pN0, G1
P23M56NET G1< 11%0.4pT1, pN0, pM0, L0, V0, pN0, G1
P24M42NET G100.3%0.2pT1(m), pN0 (0/3), pMx, L0,V0, pN0, G1
P25M68NET G1< 11.2%2.5pT2, pNx, pMx, L0, V0, pN0, G1
P26F33NET G1< 11.3%2pT1, pNx, pMx, L0, V0, pN0, G1
P27F50NET G1< 12%2.7pT2, pNx, pMx, L0, V0, pN0, G1
P28M59NET G111.2%3.5pT2, pN1(1/20), pMx, L1, V1, pN0, G1
P29F57NET G1< 11.5%0.8pT1, pN0, pMx, L0, V0, pN1, G1
P30F59NET G1< 11%2.1pT2, pN0 (0/1), pMx L0, V0, pN0, G1
P31M86NET G1< 11%0.7pT1(m), pNx, pMx, L0, V0, pN0, G1
P32F81NET G1< 10%0.8pT1, pN0 (0/14), pMx, L0, V0, pN0, G1
P33F51NET G110.5%9pT2, pN1 (7/26), pMx, L1, V0, pN0, G1
P34F45NET G110.9%2pT1(m), pN0, pM1, L0, V0, pN0, G1
P35F41NET G1< 1< 1%2pT1, pNx, pMx, L0, V0, pN0, G1
P36F40NET G1< 10.8%0.6pT1, pN0 (0/21), pM0, L0, V0, pN0, G1
P37M70NET G1< 11%0.5pT1, pN0 (0/12), pM0, L0, V0, pN0
Table 2 Primary pancreatic tumors included in the study group
Case No.Primary tumorLocalizationMitotic scoreKi67Number of CNAs in primary tumorNumber of CNAs in metastases
M_P8.1P08LN< 11%07
M_P8.2P08LN24%04
M_P10.1P10LN27%225
M_P10.2P10Peritoneal321%197
M_P12.1P12LN24%284
M_P12.2P12Liver< 1< 1%280
M_P13.1P13Liver515%137
M_P32.1P32LN< 11%5670
M_P32.2P32Peritoneal< 11%5914
M_P33.1P33Peritoneal< 11%62
M_P36.1P36Liver820%113
Table 3 Comparison of copy number alterations by array-based comparative genomic hybridization in recurrent regions in primary tumors and metastases n (%)
Recurrent regionPrimary tumorMetastasesAll tumors
n371148
Gains
01q21.3-q224 (10.8)1 (9.1)5 (10.4)
03q244 (10.8)0 (0)4 (8.3)
06p22.2-p22.19 (24.3)4 (36.4)13 (27.1)
07p21.3-p21.26 (16.2)3 (27.3)9 (18.8)
07q21.11-q21.122 (5.4)3 (27.3)5 (10.4)
08q24.34 (10.8)1 (9.1)5 (10.4)
09q34.116 (16.2)3 (27.3)9 (18.8)
11q13.1-q13.22 (5.4)2 (18.2)4 (8.3)
16p11.22 (5.4)3 (27.3)5 (10.4)
16q22.15 (13.5)1 (9.1)6 (12.5)
17p13.17 (18.9)3 (27.3)10 (20.8)
18q12.15 (13.5)0 (0)5 (10.4)
19p13.34 (10.8)0 (0)4 (8.3)
22q13.331 (2.7)2 (18.2)3 (6.3)
Losses
08q24.33 (8.1)0 (0)3 (6.3)
11q13.1-q13.22 (5.4)0 (0)2 (4.2)
16p11.22 (5.4)0 (0)2 (4.2)
16q22.11 (2.7)0 (0)1 (2.1)
17p13.11 (2.7)0 (0)1 (2.1)
22q13.330 (0)1 (9.1)1 (2.1)